| Efficacy and safety of anti–PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018 F Guisier, C Dubos-Arvis, F Viñas, H Doubre, C Ricordel, S Ropert, ... Journal of Thoracic Oncology 15 (4), 628-636, 2020 | 221 | 2020 |
| Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer C Ricordel, L Friboulet, F Facchinetti, JC Soria Annals of Oncology 29, i28-i37, 2018 | 125 | 2018 |
| Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma C Domblides, K Leroy, I Monnet, J Mazières, F Barlesi, V Gounant, ... Journal of Thoracic Oncology 15 (5), 860-866, 2020 | 100 | 2020 |
| High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU T Guy, A Créac'Hcadec, C Ricordel, A Salé, B Arnouat, JL Bizec, ... European Respiratory Journal 56 (5), 2020 | 89 | 2020 |
| Ambulatory management of large spontaneous pneumothorax with pigtail catheters F Voisin, L Sohier, Y Rochas, M Kerjouan, C Ricordel, C Belleguic, ... Annals of Emergency Medicine 64 (3), 222-228, 2014 | 71 | 2014 |
| Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the … J Mazieres, C Lafitte, C Ricordel, L Greillier, E Negre, G Zalcman, ... Journal of Clinical Oncology 40 (7), 719-728, 2022 | 49 | 2022 |
| High prevalence of somatic oncogenic driver alterations in patients with NSCLC and Li-Fraumeni syndrome L Mezquita, M Jové, E Nadal, M Kfoury, T Morán, C Ricordel, M Dhooge, ... Journal of Thoracic Oncology 15 (7), 1232-1239, 2020 | 43 | 2020 |
| Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein UL McClurg, A Nabbi, C Ricordel, S Korolchuk, S McCracken, R Heer, ... British journal of cancer 118 (5), 713-726, 2018 | 36 | 2018 |
| Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic … A Gazzah, C Ricordel, S Cousin, BC Cho, E Calvo, TM Kim, C Helissey, ... Journal of Clinical Oncology 38 (15_suppl), 9505-9505, 2020 | 34 | 2020 |
| Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non … H Lena, I Monnet, O Bylicki, C Audigier-Valette, L Falchero, ... Journal of Clinical Oncology 40 (16_suppl), 9011-9011, 2022 | 30 | 2022 |
| ING3 is required for ATM signaling and DNA repair in response to DNA double strand breaks A Mouche, J Archambeau, C Ricordel, L Chaillot, N Bigot, T Guillaudeux, ... Cell Death & Differentiation 26 (11), 2344-2357, 2019 | 29 | 2019 |
| Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced non small cell lung cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018 F Guisier, C Dubos-Arvis, F Viñas, H Doubre, C Ricordel, S Ropert, ... J Thorac Oncol 15 (4), 628-636, 2020 | 28 | 2020 |
| EFGR-mutant lung adenocarcinoma and Li-Fraumeni syndrome: report of two cases and review of the literature C Ricordel, M Labalette-Tiercin, A Lespagnol, M Kerjouan, C Dugast, ... Lung Cancer 87 (1), 80-84, 2015 | 26 | 2015 |
| Encephalitis related to immunotherapy for lung cancer: analysis of a multicenter cohort M Sanchis-Borja, C Ricordel, AM Chiappa, J Hureaux, L Odier, G Jeannin, ... Lung Cancer 143, 36-39, 2020 | 24 | 2020 |
| Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort S Baldacci, B Besse, V Avrillon, B Mennecier, J Mazieres, ... European Journal of Cancer 166, 51-59, 2022 | 18 | 2022 |
| An original case of an association of eosinophilic fasciitis with cholangitis induced by nivolumab E Le Tallec, C Ricordel, L Triquet, A Deniel, P Marcorelles, H Lena, ... Journal of Thoracic Oncology 14 (1), e13-e15, 2019 | 17 | 2019 |
| Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer N Jaksic, E Chajon, J Bellec, R Corre, C Ricordel, B de Latour, H Lena, ... Radiation Oncology 13, 1-8, 2018 | 16 | 2018 |
| Outcomes of patients with advanced NSCLC from the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France study by KRAS mutation subtypes AM Ruppert, M Beau-Faller, D Debieuvre, LH Ouafik, V Westeel, ... JTO Clinical and Research Reports 1 (3), 100052, 2020 | 15 | 2020 |
| Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or … O Bylicki, P Tomasini, G Radj, F Guisier, I Monnet, C Ricordel, ... European Journal of Cancer 183, 38-48, 2023 | 14 | 2023 |
| Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non–small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic … C Ricordel, F Barlesi, S Cousin, BC Cho, E Calvo, TM Kim, C Helissey, ... Journal of Clinical Oncology 40 (16_suppl), 9039-9039, 2022 | 14 | 2022 |
